Please assess the completion status of the following clinical trial:

Trial Title: A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* post-menopausal women, 50-85 years of age;~* any inflammatory rheumatoid disease including polymyalgia rheumatica;~* receiving treatment with 5-15 mg/day of prednisolone.~Exclusion Criteria:~* previous treatment with an iv bisphosphonate at any time;~* previous treatment with an oral bisphosphonate within the last 6 months, \>1 month of treatment within last year, or \>3 months of treatment within last 2 years;~* treatment with parathyroid hormone in last 2 years;~* inability to stand or sit in an upright position for at least 60 minutes;~* inability to swallow a tablet whole;~* history of major gastrointestinal disease.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ibandronate (Type: EXPERIMENTAL): Participants received monthly oral ibandronate (150 milligrams \[mg\]) for 12 months.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received monthly oral placebo for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).